SCHEMBL2188998

SCHEMBL2188998

O=C(O)c1cccc(N(Cc2ccccc2)S(=O)(=O)c2cccnc2)c1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
LMNA P02545 1/20 0.70
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
GRM2 Q14416 5/20 0.59
SMN1; SMN2 Q16637 1/20 0.53
CYP11B1 P15538 1/20 0.52
TRPM8 Q7Z2W7 2/20 0.50
PTGES O14684 2/20 0.50
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
ALOX5 P09917 1/20 0.50
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246857 0.91 MEN1 (0.65) ALDH1A1LMNAMEN1KMT2AGRM2
SCHEMBL2189346 0.88 LMNA (0.85) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL303030 0.86 GRM2 (0.54) ALDH1A1LMNAMEN1KMT2AGRM2
SCHEMBL3279825 0.84 CYP11B1 (0.53) ALDH1A1LMNAMEN1KMT2AGRM2
SCHEMBL10250146 0.83 LMNA (1.00) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL2186013 0.81 ALDH1A1 (0.77) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3633622 0.81 GRM2 (0.67) ALDH1A1LMNAMEN1KMT2AGRM2
SCHEMBL2192252 0.80 LMNA (0.71) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL13064484 0.80 MEN1 (0.78) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL302891 0.79 HTR2C (0.66) ALDH1A1LMNAMEN1KMT2AGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 ALDH1A1 1360/4885LMNA 1619/4885MEN1 608/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 ALDH1A1 3795/4885LMNA 2145/4885MEN1 2747/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 ALDH1A1 1360/4885LMNA 1619/4885MEN1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.